Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant in the SARS-CoV-2 Subunit Mucosal Vaccine

NCT06768697 is registered in ClinicalTrials.gov with Shanghai Public Health Clinical Center as lead sponsor.

NCT NCT06768697
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06768697 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity Evaluation of the Recombinant Flagellin Protein Adjuvant in the SARS-CoV-2 Subunit Mucosal Vaccine
Lead sponsor
Shanghai Public Health Clinical Center
Phase
Phase 1
Overall status
Not yet recruiting
Start date
December 30, 2024
Completion date
December 30, 2025
Enrollment
60 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

covid - 19